Lunresertib

Lunresertib is an investigational new drug that is being evaluated for the treatment of cancer. It is an oral small molecule inhibitor of PKMYT1, developed by Repare Therapeutics.^[1] This drug targets cell cycle regulation in tumors with specific genetic alterations, including CCNE1 amplifications or FBXW7 and PPP2R1A loss of function mutations. It is currently in phase 1/2 clinical trials, both as monotherapy or in combination with camonsertib, an ATR inhibitor.^[2]

Lunresertib

Clinical data
Other names	RP-6306
Identifiers
IUPAC name (1P)-{{#parsoidfragment:2}}H-pyrrolo[2,3-b]pyridine-3-carboxamide
CAS Number	2719793-90-3
PubChem CID	156869388
ChemSpider	115008046
UNII	N95U3A7N57
KEGG	D12736
ChEMBL	ChEMBL5199076
Chemical and physical data
Formula	C18H20N4O2
Molar mass	324.384 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1=C(C(=C(C=C1)O)C)N2C(=C(C3=C2N=C(C(=C3)C)C)C(=O)N)N
InChI InChI=InChI=1S/C18H20N4O2/c1-8-5-6-13(23)10(3)15(8)22-16(19)14(17(20)24)12-7-9(2)11(4)21-18(12)22/h5-7,23H,19H2,1-4H3,(H2,20,24) Key:ARBRHWRTXPWZGN-UHFFFAOYSA-N